Clinical Trial

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Study acronym: Elevate-HF
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Trial Details
NCT Number NCT07761117
Lead Sponsor AstraZeneca
Conditions Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Enrollment 6,950 participants
Start Date 2026-08-28
Primary Completion 2029-09-03 (estimated)
Study Completion 2029-09-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-12